Although no direct pharmacological activators of RASSF1A are currently available, epigenetic therapies aimed at restoring its expression, such as DNA methyltransferase (DNMT) inhibitors, have shown efficacy in reactivating RASSF1A in other tumour types [67,68]. The gene discussed is RASSF1; the disease is neoplasm.